Kymab Strengthens Management Team With Two Senior Appointments - 6/3

UK-based monoclonal antibody biopharmaceutical company Kymab has announced the appointment of Steve Arkinstall as Chief Scientific Officer and Nigel Clark as Vice President and Head of Business Development. Mr Arkinstall brings overs 25 years' experience across biopharmaceutical research and development, having worked across several disease areas and specialising in drug target validation, R&D strategic design, antibody discovery and protein engineering. He joins Kymab from Merck Serono, where over his 16 year career he has held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of Global Technologies and External Innovation. 

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.